Key points are not available for this paper at this time.
The Global Initiative for Asthma recommends gradually stepping down treatments to the lowest oral/inhaled corticosteroid doses that control symptoms and exacerbations. Tezepelumab treatment enabled reductions in oral/inhaled corticosteroid doses versus placebo while preserving asthma symptom control and lung function.
Wechsler et al. (Thu,) studied this question.